SCHEMBL7095873

SCHEMBL7095873

CC1Oc2ccc(C(Cc3ccccc3F)NC(=O)OC(C)(C)C)cc2NC1=S

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.42
CTSK P43235 1/20 0.42
SCN9A Q15858 12/20 0.40
PTPN1 P18031 1/20 0.38
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
RCE1 Q9Y256 1/20 0.35
MAPT P10636 2/20 0.35
HPGD P15428 2/20 0.35
HTT P42858 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
PLA2G1B P04054 1/20 0.35
XBP1 P17861 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35
SCN10A Q9Y5Y9 1/20 0.34
P4HB P07237 2/20 0.33
POLB P06746 1/20 0.33
IDO1 P14902 1/20 0.33
JAK2 O60674 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7708086 0.91 CTSS (0.43) CTSSCTSKSCN9APTPN1ALDH1A1
SCHEMBL7087735 0.90 MC4R (0.36) CTSKSCN9AALDH1A1KDM4ERCE1
SCHEMBL7704943 0.88 ALDH1A1 (0.43) CTSSCTSKALDH1A1MAPTHPGD
SCHEMBL7091085 0.87 NPSR1 (0.35) CTSSCTSKALDH1A1KDM4ERCE1
SCHEMBL7094067 0.87 HPGD (0.41) CTSSCTSKSCN9AALDH1A1KDM4E
SCHEMBL7087725 0.86 CTSS (0.41) CTSSCTSKSCN9AALDH1A1MAPT
SCHEMBL7090483 0.86 CTSS (0.45) CTSSCTSKSCN9AALDH1A1KDM4E
SCHEMBL7093383 0.84 MC4R (0.41) ALDH1A1KDM4ERCE1MAPTHPGD
SCHEMBL7095640 0.83 ALDH1A1 (0.37) ALDH1A1KDM4ERCE1MAPTHPGD
SCHEMBL7092472 0.83 HSD17B10 (0.37) ALDH1A1MAPTHPGDHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed